TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31574157
Drug: Dural Sealant
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dural Sealant Patch (DSP)
Study: 20381654
Drug: NT-pro-BNP level
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-pro-BNP level > or = 260 pg/ml
Study: 16647139
Drug: Personality measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personality measures before and after treatment
Study: 14563572
Drug: Ad5FGF‐4 gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5FGF‐4 gene therapy
Study: 10821451
Drug: Pooled results
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled results from both trials; treatment group from both trials.
Study: 8888383
Drug: Nicotine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (administered subcutaneously or by cigarette smoking)
Study: 8888383
Drug: Amphetamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (5 mg administered 90 min before testing)
Study: 1892303
Drug: formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: formoterol 12 micrograms twice a day
Study: 1892303
Drug: albuterol 200
Normalized name: ALBUTEROL 200MCG CAP,INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: albuterol 200 micrograms four times a day
Study: 29388929
Drug: Vermel electrophoresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vermel electrophoresis with 1% sodium bromide solution
Study: 25362228
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) dalteparin
Study: 14749693
Drug: Lanreotide 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 100 microg/h infusion for 8 hours
Study: 14749693
Drug: Lanreotide 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 800 microg bolus injection
Study: 11679509
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (100 mg on days 5-9)
Study: 9129858
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (specific dosage and duration not mentioned)
Study: 9129858
Drug: Randomized recommendation
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized recommendation to use or not use hormone therapy
Study: 3591257
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (225-375 micrograms) + diazepam (5-15 mg)
Study: 3591257
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg the night before and 300 mg in the morning) + diazepam
Study: 20874659
Drug: Sex hormone-binding
Normalized name: Testosterone bound to sex hormone-binding globulin (SHBG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone-binding globulin
Study: 24336948
Drug: Pacemaker therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacemaker therapy in patients with negative tilt test (TT-), 26 patients
Study: 24336948
Drug: Pacemaker therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacemaker therapy in patients with positive tilt test (TT+), 26 patients
Study: 17353402
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) solution
Study: 11528550
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment with initial leukaemic blood blast count < 1000 blasts/microliter
Study: 11528550
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment with initial leukaemic blood blast count >= 1000 blasts/microliter
Study: 11528550
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with < 1000 blasts/microliter on day eight of treatment but increasing blast count
Study: 7607785
Drug: Mazindol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (0.5 mg, three tablets per day for three months)
Study: 7607785
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three tablets per day for three months)
Study: 29739354
Drug: Icodextrin solution
Normalized name: icodextrin Irrigation Solution
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icodextrin solution (ICO)
Study: 29739354
Drug: Glucose-based solution
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based solution (GLU)
Study: 24373856
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical fluoride treatment (active caries)
Study: 23593205
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulfate (STS) 10 mmol twice a day for 7 days
Study: 19052406
Drug: Calcipotriol 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 0.005% ointment applied twice daily
Study: 19052406
Drug: Tazarotene 0.05%
Normalized name: TAZAROTENE 0.05% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.05% gel applied once daily
Study: 19052406
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel applied once daily
Study: 11673585
Drug: 8.0 mg
Normalized name: KAOLIN 8.0 mg in 100 mL ORAL LIQUID [Diarrhea Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.0 mg albuterol twice daily
Study: 11673585
Drug: 16.0 mg
Normalized name: MENTHOL 16.0 mg ORAL LOZENGE [COOL RELIEF LEMON FROST ORAL ANESTHETIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.0 mg albuterol twice daily
Study: 30877066
Drug: Lycium barbarum
Normalized name: LYCIUM BARBARUM FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycium barbarum (LB) supplement
Study: 24128861
Drug: Fludarabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine plus cyclophosphamide (FC) chemotherapy
Study: 22506139
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy and NMES
Study: 22506139
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy only
Study: 19692530
Drug: Tart cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart cherry juice (240 mL twice daily for 14 days)
Study: 19692530
Drug: Placebo (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (240 mL twice daily for 14 days)
Study: 16508640
Drug: CHOP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP (cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², prednisolone 100 mg)
Study: 16508640
Drug: PMitCEBO (mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMitCEBO (mitoxantrone 7 mg/m², cyclophosphamide 300 mg/m², etoposide 150 mg/m², vincristine 1.4 mg/m², bleomycin 10 mg/m², prednisolone 50 mg)
Study: 11020593
Drug: Baseline misconceptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline misconceptions (e.g., washing genitals after sex, urinating after sex, douching, use of oral contraceptives)
Study: 9068812
Drug: Killed Mycobacterium
Normalized name: Heat Killed Mycobacterium W Immunomodulator
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed Mycobacterium vaccae as immunotherapy
Study: 3096133
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (12.5 to 50 mg) applied to the arm
Study: 3096133
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (12.5 to 50 mg) applied to the chest
Study: 3096133
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (12.5 to 50 mg) applied to the thigh
Study: 19675365
Drug: Low alcohol
Normalized name: Low alcohol beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low alcohol dose
Study: 19675365
Drug: High alcohol
Normalized name: High alcohol lager
Approvals — FDA: no, EMA: no, PMDA: no
Description: High alcohol dose
Study: 17343006
Drug: Fructus Bruceae
Normalized name: Brucea javanica fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructus Bruceae oil emulsion (FBE) combined with chemotherapy (GP regimen)
Study: 17343006
Drug: Chemotherapy (GP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (GP regimen) only
Study: 15295219
Drug: Palivizumab 5
Normalized name: PALIVIZUMAB 50MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab 5 mg/kg
Study: 3382595
Drug: Metoclopramide with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide with oral controlled release morphine
Study: 3382595
Drug: Oral controlled
Normalized name: Afeditab CR Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral controlled release morphine alone
Study: 30900194
Drug: Animal Assisted
Normalized name: animals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal Assisted Therapy (AAT) with dogs
Study: 22964343
Drug: Immediate Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate Intervention Group (IIG) - Relaxation therapy days 3-6
Study: 22964343
Drug: Delayed Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed Intervention Group (DIG) - Relaxation therapy days 6-9
Study: 17404163
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg/ramipril 5 mg
Study: 17404163
Drug: Verapamil 180
Normalized name: verapamil 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 180 mg/trandolapril 2 mg
Study: 17404163
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate 95 mg/hydrochlorothiazide 12.5 mg
Study: 7554709
Drug: Mofegiline (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mofegiline (single oral doses up to 48 mg)
Study: 7554709
Drug: Mofegiline (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mofegiline (daily doses for 28 days up to 24 mg)
Study: 7554709
Drug: Mofegiline (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mofegiline (doses up to 24 mg)
Study: 7554709
Drug: Mofegiline (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mofegiline (doses up to 48 mg and 24 mg)
Study: 7554709
Drug: Mofegiline (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mofegiline (48 mg single dose and 24 mg multiple daily dose)
Study: 2124210
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g pefloxacin, given orally
Study: 2124210
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g cefotaxime, given intramuscularly
Study: 6103255
Drug: Heparin (1
Normalized name: 2,3-o-Desulfated heparin (12000 da)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1 IU kg‐1 h‐1) administered intravenously for 3‐5 days during and after operation.
Study: 6103255
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no heparin treatment).
Study: 6103255
Drug: Heparin administration.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration.
Study: 31099859
Drug: Twice-Daily Radiotherapy
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-Daily Radiotherapy (TDRT)
Study: 31099859
Drug: Once-Daily Radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-Daily Radiotherapy (ODRT)
Study: 20234886
Drug: Oxidized surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxidized surface implant
Study: 20234886
Drug: Machined surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Machined surface implant
Study: 15842028
Drug: 8-session Short
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-session Short Psychodynamic Supportive Psychotherapy + pharmacotherapy
Study: 15842028
Drug: 16-session Short
Normalized name: short ragweed pollen extracts
DrugBank: Ambrosia artemisiifolia pollen (DB10385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-session Short Psychodynamic Supportive Psychotherapy + pharmacotherapy
Study: 30003429
Drug: Physician-implemented medication
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician-implemented medication screening tool
Study: 30003429
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical and pharmaceutical care
Study: 26242730
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg orally every twenty four hours)
Study: 24217313
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (5,000 U weekly for 8 weeks)
Study: 19615313
Drug: Feitai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feitai Capsule
Study: 12720535
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate therapy in conjunction with anti-rheumatic therapy
Study: 12720535
Drug: Anti-rheumatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-rheumatic therapy alone (without etidronate)
Study: 8408474
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + C-peptide
Study: 3513531
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg guanfacine daily at bedtime for 8 weeks
Study: 28664389
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (HPLT 970 ± 15 nm, 3.2 W (50%), 35-6000 Hz, 240 s for four consecutive days, once a day)
Study: 28664389
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (sham treatment)
Study: 24601174
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors (sitagliptin) in combination with metformin
Study: 12730857
Drug: Y-27632 (Rho
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y-27632 (Rho kinase inhibitor)
Study: 11265390
Drug: Cochlear function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear function estimation by otoacoustic emission in children treated with cytostatic drugs for leukemia
Study: 11265390
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group of healthy children who have never suffered from ear diseases and have never used ototoxic drugs
Study: 1335217
Drug: Buspirone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (45 to 60 mg/day)
Study: 3882525
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg pirenzepine
Study: 3882525
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg pirenzepine
Study: 24222526
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural treatment (CBT) programme supplemented with culturally sensitive aspects (CsCBT)
Study: 24222526
Drug: Culturally sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally sensitive exercise therapy (CsET)
Study: 17293731
Drug: Bupropion 150
Normalized name: BUPROPION 150MG (SMK-C) 12HR SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 150 mg twice daily
Study: 7910322
Drug: Biosynthetic growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic growth hormone (GH) at 4 IU per m2 per day
Study: 7910322
Drug: Biosynthetic growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic growth hormone (GH) at 8 IU per m2 per day
Study: 3349549
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml coffee (Group 1)
Study: 3349549
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml orange juice (Group 2)
Study: 24367124
Drug: 12-month collaborative
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month collaborative care program involving antidepressants and psychotherapy
Study: 14748464
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg iv 30 min prior to cisplatin, followed by 8 mg orally for 24 h)
Study: 14748464
Drug: Metoclopramide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (20 mg iv 30 min prior to cisplatin, followed by 20 mg orally for 24 h)
Study: 8873834
Drug: Parenteral sulbactam-ampicillin
Normalized name: ampicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral sulbactam-ampicillin (1.5 g, q.i.d.)
Study: 1954180
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in patients with more than 10% positive NSE cells
Study: 1954180
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in patients with Chromogranin A
Study: 6831946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of phentolamine and albuterol
Study: 30075513
Drug: Ramosetron 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.6 mg added to 2-day intravenous patient-controlled analgesia (IV-PCA)
Study: 30075513
Drug: Ramosetron 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 1.2 mg added to 2-day intravenous patient-controlled analgesia (IV-PCA)
Study: 1360145
Drug: Trimethoprim-sulfamethoxazole 480
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole 480 mg once a day
Study: 1360145
Drug: Trimethoprim-sulfamethoxazole 960
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole 960 mg once a day
Study: 22075088
Drug: Standard multi-dose
Normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multi-dose hepatitis B vaccine schedule (0, 1, and 6 months)
Study: 22075088
Drug: Accelerated hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hepatitis B vaccine schedule (0, 1, and 2 months)
Study: 22075088
Drug: Participants injecting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants injecting drugs more than once a day
Study: 17912568
Drug: DHA +
Normalized name: PNV-DHA + Docusate Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA + ARA, soy‐based formula supplemented with at least 17 mg DHA/100 kcal and 34 mg ARA/100 kcal
Study: 15512377
Drug: sultrin (sulphathiazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: sultrin (sulphathiazole 3.42%, sulphacetamide 2.86%, sulphabenzamide 3.7%) pessaries: one pessary twice daily for 5 days
Study: 1662266
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg per day for 3 weeks)
Study: 27052530
Drug: Dairy diet
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy diet (3 servings/d of dairy: 375 mL 1% milk-fat milk, 175 g 1.5% MF yogurt, and 30 g of 34% MF cheese)
Study: 25204404
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1,000 mg/day
Study: 22739534
Drug: L-arginine buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine buffered with citric acid (ARG.CITR)
Study: 22739534
Drug: L-arginine buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine buffered with HCl (ARG.HCl)
Study: 21057255
Drug: Family-based pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based pediatric obesity program (treatment group)
Study: 2732141
Drug: FCE 22101
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 22101 (500 mg, 1000 mg, 750 mg, 1500 mg, 2000 mg)
Study: 2732141
Drug: FCE 22101
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 22101 (1000 mg) with probenecid
Study: 2732141
Drug: FCE 22101
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 22101 (1000 mg) without probenecid
Study: 2732141
Drug: FCE 22101
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 22101 (1000 mg) via im injection
Study: 2732141
Drug: FCE 22101
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 22101 (continuous infusion at 280 mg/h)
Study: 30241001
Drug: Buparlisib plus
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib plus fulvestrant (100 mg/day buparlisib continuously in 28-day cycles; 500 mg fulvestrant on cycle 1 day 15 and day 1 of subsequent cycles)
Study: 30241001
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus fulvestrant (placebo continuously in 28-day cycles; 500 mg fulvestrant on cycle 1 day 15 and day 1 of subsequent cycles)
Study: 26149444
Drug: Stepped-care intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care intervention package for depression, delivered by trained primary health care workers, including psychological interventions and medication based on severity and response.
Study: 17241576
Drug: Efalizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (1 mg/kg for 12 weeks)
Study: 17241576
Drug: Efalizumab (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (36 months continuous treatment)
Study: 10953853
Drug: Intensive control
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive control with metformin